Grand Pharmaceutical Group Limited

Grand Journey for A Healthier World

GP (HK) Announces 2021 interim Results

The total profit for the period attributable to owners of the Company amounted to approximately HK$1,202.5 million with an increment of approximately 67.4% as compared with the corresponding period in 2020.

Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud

Corporate News

GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs

Corporate News

GP (HK)’s Global Innovative RDC Drug TLX591-CDX Was Approved in The United States, Another Milestone Progress of the Group’s Innovative Products’ Commercialization

Corporate News

GP (HK)’s Global Innovative Drug STC3141 Successfully Completed the Enrolment and Dosing of All Patients in Phase IIa Clinical Trial for COVID-19 in Europe, Another Milestone in Global Clinical Trial, and Consolidating the Strategic Plan in the Field of Severe Anti-infection

Corporate News

GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment

Grand Journey for A Healthier World

GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs

GP (HK)’s Global Innovative RDC Drug TLX591-CDX Was Approved in The United States, Another Milestone Progress of the Group’s Innovative Products’ Commercialization

GP (HK)’s Global Innovative Drug STC3141 Successfully Completed the Enrolment and Dosing of All Patients in Phase IIa Clinical Trial for COVID-19 in Europe, Another Milestone in Global Clinical Trial, and Consolidating the Strategic Plan in the Field of Severe Anti-infection

GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment

Popular News

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

Yuanda medicine gets sepsis innovative medicine again

GP (HK) Announces 2019 Annual Results

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

Media Report

Yuanda medicine gets sepsis innovative medicine again